Prothena Corporation plc (PRTA) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Prothena Corporation plc (PRTA) Healthcare & Pipeline Overview

Prothena Corporation plc, a clinical-stage biotechnology firm based in Dublin, Ireland, specializes in developing innovative therapies for neurodegenerative and rare diseases. With a pipeline focused on Alzheimer's, Parkinson's, and amyloidosis, Prothena partners with major pharmaceutical companies like Roche and Bristol-Myers Squibb to advance its clinical programs.

What Is the Investment Thesis for PRTA?

Prothena presents a high-risk, high-reward investment profile typical of clinical-stage biotech companies. Key value drivers include the successful progression and eventual approval of its lead drug candidates, particularly Birtamimab for AL amyloidosis, which is in Phase III trials. Positive data readouts from ongoing clinical trials, especially for Prasinezumab in Parkinson's disease, could serve as significant catalysts. The company's partnerships with Roche and Bristol-Myers Squibb provide validation and potential revenue streams. However, the negative profit margin of -260.9% and the inherent risks of clinical development, including trial failures and regulatory hurdles, must be considered. The company's beta of -0.33 suggests lower volatility than the market, but this may not fully capture the risk associated with its pipeline.

Based on FMP financials and quantitative analysis

PRTA Key Highlights

Market capitalization of $460M reflects investor sentiment regarding the potential of Prothena's pipeline.

• Negative profit margin of -260.9% indicates that the company is currently investing heavily in research and development.
• Gross margin of 46.8% suggests potential for profitability upon successful commercialization of products.
• Birtamimab in Phase III clinical trial represents a near-term catalyst with potential for significant revenue generation.
• Partnerships with Roche and Bristol-Myers Squibb validate Prothena's technology and provide financial support.

Who Are PRTA's Competitors?

PRTA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PRTA's Key Strengths?

Late-stage clinical pipeline with potential for near-term revenue.

• Strategic partnerships with major pharmaceutical companies.
• Proprietary technology and intellectual property.
• Experienced management team with expertise in drug development.

What Are PRTA's Weaknesses?

High R&D expenses and negative profit margin.

• Reliance on clinical trial outcomes and regulatory approvals.
• Limited commercial infrastructure.
• Concentration of pipeline in specific disease areas.

What Could Drive PRTA Stock Higher?

PRTA catalyst: Data readout from Phase III clinical trial of Birtamimab for AL amyloidosis (expected in late 2026).

• Data readout from Phase IIb clinical trial of Prasinezumab for Parkinson's disease (expected in 2027).
• Advancement of PRX012 into Phase I clinical trials for Alzheimer's disease (timeline dependent on preclinical data).
• Potential milestone payments from Roche and Bristol-Myers Squibb partnerships based on clinical and regulatory progress.
• Presentation of preclinical data at scientific conferences.

What Are the Key Risks for PRTA?

Negative return on equity (-15.0%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure of Birtamimab in Phase III clinical trial, leading to significant loss of value.
• Regulatory delays or rejection of Birtamimab by FDA or EMA.
• Competition from other companies developing therapies for Alzheimer's and Parkinson's diseases.
• High cash burn rate and need for additional financing.
• Dependence on partnerships with Roche and Bristol-Myers Squibb.

What Are the Growth Opportunities for PRTA?

• Birtamimab for AL Amyloidosis: Birtamimab, currently in Phase III clinical trials, targets AL amyloidosis, a rare and life-threatening disease. If approved, Birtamimab could capture a significant share of the limited treatment market, estimated to reach several hundred million dollars annually. The timeline for potential FDA approval is approximately 2-3 years, contingent on positive trial results. Prothena's competitive advantage lies in Birtamimab's unique mechanism of action and its potential to improve survival rates in AL amyloidosis patients.
• Prasinezumab for Parkinson's Disease: Prasinezumab, a humanized monoclonal antibody in Phase IIb clinical trial, aims to slow the progression of Parkinson's disease. Positive Phase IIb results could accelerate development and attract further investment. Prothena's approach targets alpha-synuclein, a key protein implicated in Parkinson's pathology, offering a potentially disease-modifying therapy.
• PRX012 for Alzheimer's Disease: PRX012, a preclinical program targeting Alzheimer's disease, represents a longer-term growth opportunity. The Alzheimer's market is one of the largest in pharmaceuticals, with significant unmet need. While still in early stages, PRX012's novel mechanism of action could differentiate it from existing and emerging therapies. The timeline for clinical trials is several years, but successful development could lead to substantial commercial opportunities.
• Partnerships with Roche and Bristol-Myers Squibb: Prothena's collaborations with Roche and Bristol-Myers Squibb provide access to resources, expertise, and potential revenue streams. These partnerships validate Prothena's technology and de-risk its development programs. Milestone payments and royalties from partnered programs could contribute significantly to Prothena's financial performance over the next decade. Expanding these partnerships or securing new collaborations represents a key growth driver.
• Dual Aß-Tau Vaccine for Alzheimer's Disease: Prothena's dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease is another preclinical program with significant potential. This vaccine aims to target two key proteins implicated in Alzheimer's pathology. Although still in early stages of development, successful preclinical results could lead to clinical trials and eventual commercialization. The Alzheimer's vaccine market could be substantial, driven by the desire for preventative therapies.

What Opportunities Does PRTA Have?

• Expansion of pipeline through internal discovery and external collaborations.
• Advancement of preclinical programs into clinical development.
• Potential for breakthrough therapies in areas with high unmet need.
• Market growth in neurodegenerative disease therapies.

What Threats Does PRTA Face?

• Clinical trial failures and regulatory setbacks.
• Competition from established pharmaceutical companies.
• Patent expirations and generic/biosimilar competition.
• Changes in healthcare regulations and reimbursement policies.

What Are PRTA's Competitive Advantages?

• Proprietary technology and intellectual property in novel therapeutic targets.
• Clinical-stage pipeline with potential for first-in-class or best-in-class therapies.
• Strategic partnerships with Roche and Bristol-Myers Squibb.
• Expertise in developing antibodies and vaccines for complex diseases.

What Does PRTA Do?

Founded in 2012, Prothena Corporation plc is a biotechnology company dedicated to discovering and developing novel therapies for life-threatening diseases. Headquartered in Dublin, Ireland, the company focuses primarily on neurodegenerative diseases and amyloidosis. Prothena's pipeline includes several clinical-stage programs, such as Birtamimab, an investigational humanized antibody in Phase III clinical trial for AL amyloidosis, and Prasinezumab, a humanized monoclonal antibody in Phase IIb clinical trial for Parkinson's disease. Other programs include PRX004, which completed Phase I clinical trial for Transthyretin amyloidosis, and PRX005, in Phase I clinical trial for Alzheimer's disease. In addition to clinical-stage assets, Prothena has preclinical programs like PRX012 for Alzheimer's disease and a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's. The company collaborates with major pharmaceutical firms, including F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., to develop and commercialize antibodies targeting alpha-synuclein, and with Bristol-Myers Squibb to develop antibodies for unspecified targets. Prothena operates primarily in the United States, focusing on addressing significant unmet medical needs in severe and debilitating diseases.

What Products and Services Does PRTA Offer?

• Develop novel therapies for life-threatening diseases.
• Focus on neurodegenerative diseases like Alzheimer's and Parkinson's.
• Develop treatments for amyloidosis, including AL amyloidosis and Transthyretin amyloidosis.
• Advance clinical-stage programs through rigorous trials.
• Collaborate with major pharmaceutical companies for development and commercialization.
• Discover and develop antibodies targeting key proteins implicated in disease pathology.
• Create vaccines for the prevention of Alzheimer's disease.

How Does PRTA Make Money?

• Develops and patents novel therapeutic candidates.
• Out-licenses or co-develops programs with larger pharmaceutical companies.
• Generates revenue through milestone payments, royalties, and potential product sales.
• Focuses on high-value, unmet medical needs in specialized disease areas.

What Industry Does PRTA Operate In?

Prothena operates within the competitive biotechnology industry, characterized by high R&D spending, lengthy development timelines, and significant regulatory hurdles. The market for neurodegenerative disease therapies, particularly Alzheimer's and Parkinson's, is substantial and growing due to aging populations. Competition includes major pharmaceutical companies and specialized biotech firms. Prothena differentiates itself through its focus on novel targets and its partnerships with established industry players. The success of companies in this sector hinges on clinical trial outcomes and regulatory approvals.

Who Are PRTA's Key Customers?

• Patients suffering from neurodegenerative diseases (Alzheimer's, Parkinson's).
• Patients with amyloidosis (AL amyloidosis, Transthyretin amyloidosis).
• Pharmaceutical companies seeking to expand their pipelines through partnerships.
• Healthcare providers prescribing treatments for these diseases.

Wall Street analysts project Prothena Corporation plc revenue of about $83.3M for fiscal 2026, with EPS near $-0.07. The estimate reflects 4 contributing analysts.

Quarterly Financial Performance: Prothena Corporation plc

Revenue for Prothena Corporation plc came in at $1.0M during Q2 2026, a 98.0% contraction versus the preceding quarter. The company recorded a net loss of $18.6M, with diluted EPS of $-0.36. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, PRTA averaged $-0.21 in diluted EPS.

PRTA Valuation & Market Position

With a $460M market cap, Prothena Corporation plc sits in the small-cap segment of the market. Relative to its peer group, PRTA's quantitative score of 51/100 is below the peer average of 81/100.

Return on equity for Prothena Corporation plc stands at -15.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -14.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -13.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 25.05 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -9.5%, the inverse of the P/E and a quick read on earnings relative to price.

Prothena Corporation plc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 13.25 places it in the safe zone, indicating low near-term bankruptcy risk.

Prothena Corporation plc has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 26.7% above estimates on average.

Company Profile

Prothena Corporation plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dublin, IE. The company is led by CEO Gene G. Kinney. PRTA has traded publicly since 2012.

PRTA Financials

PRTA Latest News

PRTA Analyst Consensus

PRTA MoonshotScore

What Investors Ask About Prothena Corporation plc (PRTA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources